Daratumumab
Showing 26 - 50 of 273
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
May 4, 2023
Immune Thrombocytopenia Trial (Daratumumab Injection)
Not yet recruiting
- Immune Thrombocytopenia
- Daratumumab Injection
- (no location specified)
Sep 28, 2022
Multiple Myeloma Trial in United States (Daratumumab, Lenalidomide, Bortezomib)
Recruiting
- Multiple Myeloma
- Daratumumab
- +3 more
-
Ann Arbor, Michigan
- +3 more
Jan 19, 2023
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder Trial in Tianjin (Daratumumab, Placebo)
Recruiting
- Neuromyelitis Optica
- +2 more
- Daratumumab
- Placebo
-
Tianjin, Tianjin, ChinaTianjin Medical University General Hospital
Oct 19, 2022
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston
Completed
- High Risk Myelodysplastic Syndrome
- +2 more
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Nov 21, 2022
AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease Trial in San Francisco (Venetoclax, Dexamethasone,
Not yet recruiting
- AL Amyloidosis
- +2 more
- Venetoclax
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 16, 2022
Patient and Healthcare Provider Satisfaction of Daratumumab Use
Recruiting
- Multiple Myeloma
- +5 more
- Daratumumab
-
Frankfurt, Hessen, GermanyCentrum für Hämatologie und Onkologie Bethanien
Aug 1, 2022
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis Trial in Duarte (biological, drug, procedure, other)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- +2 more
- Daratumumab
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
T-cell Acute Lymphoblastic Leukemia Trial in Chicago (Daratumumab / Hyaluronidase Injection)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Daratumumab / Hyaluronidase Injection
-
Chicago, IllinoisNorthwestern
Jun 17, 2022
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia Trial (Darzalex)
Not yet recruiting
- Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
- (no location specified)
Feb 27, 2023
Daratumumab in Combination With Bortezomib, Thalidomide, and
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
- (no location specified)
Sep 27, 2022
Multiple Myeloma Trial in United States (daratumumab, carfilzomib, lenalidomide)
Active, not recruiting
- Multiple Myeloma
- daratumumab
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Dec 28, 2022
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in New York (Daratumumab, Clarithromycin,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +3 more
-
New York, New YorkWeill Cornell Medicine - Multiple Myeloma Center
Jun 8, 2022
High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)
Not yet recruiting
- High-Risk de Novo Multiple Myeloma
- Daratumumab
- +5 more
-
Badalona, Spain
- +9 more
Apr 27, 2023
AL Amyloidosis Trial in Catanzaro, Pavia, Rome (daratumumab and pomalidomide)
Recruiting
- AL Amyloidosis
- daratumumab and pomalidomide
-
Catanzaro, Italy
- +2 more
Aug 3, 2022
AL Amyloidosis Trial in Scottsdale, Jacksonville, Rochester (procedure, biological, other)
Not yet recruiting
- AL Amyloidosis
- Bone Marrow Biopsy
- +4 more
-
Scottsdale, Arizona
- +2 more
Jun 2, 2023
Multiple Myeloma Trial in Cologne (Daratumumab)
Recruiting
- Multiple Myeloma
- Daratumumab
-
Cologne, GermanyUniversity of Cologne
Apr 4, 2022
Selinexor, Daratumumab and Dexamethasone in Chinese Multiple
Not yet recruiting
- Multiple Myeloma at First Relapse
- (no location specified)
Sep 27, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)
Recruiting
- Multiple Myeloma
- Teclistamab (Tec)
- +4 more
-
Berlin, Germany
- +8 more
Jan 19, 2023
Multiple Myeloma Trial in United States (TTI-622, Daratumumab Hyaluronidase-fihj)
Recruiting
- Multiple Myeloma
- TTI-622
- Daratumumab Hyaluronidase-fihj
-
Basking Ridge, New Jersey
- +6 more
Dec 8, 2022
Lupus Nephritis Trial in Rochester (Daratumumab)
Recruiting
- Lupus Nephritis
- Daratumumab
-
Rochester, MinnesotaMayo Clinic in Rochester
May 23, 2022